Nyhetsarkiv

U.S. FDA Approves ZALTRAP® (ziv-aflibercept) after Priority Review for Previously Treated Metastatic Colorectal Cancer

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.

20 Juni 2012 10:37

Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes

Sanofi (EURONEXT: SAN and NYSE: SNY) and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, today announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders. The collaboration was unveiled at the 2012 Bio International Convention in Boston, Mass.

15 Juni 2012 13:52

Sanofi Voted Leading Pan-European Quoted Company for Investor Relations in the 2012 Thomson Reuters Extel Survey

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it was granted the award for “Leading Pan-European Quoted Company for Investor Relations” in the 2012 Thomson Reuters Extel Survey. Considered the leading benchmark for excellence in Investor Relations (IR), the survey highlights achievement across companies listed in Europe.

12 Juni 2012 15:20

Sanofi presenterar resultat från världens största och längsta randomiserade studie inkluderande personer med tidig typ 2-diabetes och förstadier till typ 2-diabetes

Den internationella studien ORIGIN (Outcome Reduction with Initial Glargine Intervention) har undersökt om det går att förhindra eller skjuta upp kardiovaskulära händelser som kan följa av typ 2-diabetes och om man kan förhindra utvecklingen av typ 2-diabetes hos personer som riskera få denna sjukdom, genom att behandla med Lantus® (insulin glargin) på ett tidigare stadium än vad som görs idag.

12 Juni 2012 13:40

Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA™ (alemtuzumab) for Multiple Sclerosis

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of LEMTRADA™ (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS).

12 Juni 2012 10:52

New Epidemiological Data Provide Additional Safety Evidence for Lantus® – No increased risk of cancer found with Lantus® in new European and U.S. observational studies

Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California, and at the University of North Carolina in the United States.

11 Juni 2012 13:16

Lantus® Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes

Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus® (insulin glargine [rDNA origin] injection) versus sitagliptin. These data from the EASIE study were presented at the American Diabetes Association 72nd Scientific Sessions.

11 Juni 2012 09:12

Läkemedel från ödlesaliv sänker blodsockret - Fas 3-studier på patienter med typ 2-diabetes visar att behandling med lixisenatid signifikant minskar långtidsblodsockret (HbA1c).

Sanofi presenterar studieresultat från prövningsprogrammet GetGoal som visar att lixisenatid, som tillägg till basinsulin och perorala diabetesläkemedel, signifikant sänker långtidsblodsockret (HbA1c) både hos de patienter med typ 2-diabetes som nyligen har påbörjat sin behandling med insulin, och hos de patienter som har behandlats med insulin en längre tid (i genomsnitt 3,1 år).

1 Juni 2012 13:10

Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIOTM* (teriflunomide) in Relapsing Multiple Sclerosis

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today top-line results from the TOWER (Teriflunomide Oral in people With relapsing remitting multiplE scleRosis) trial that assessed the efficacy and safety of once-daily, oral teriflunomide in patients with relapsing forms of multiple sclerosis (MS).

29 Maj 2012 17:04

Sanofi Inaugurates Lantus® SoloSTAR® Pen Assembly Plant in its Beijing Facility - The Group Pledges Continuous Commitment to Diabetes Management in China

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the inauguration of a new assembling and packaging line to produce its flagship pre-filled insulin injection pen Lantus® SoloSTAR® at its Beijing plant located at the Beijing Economic-Technological Development Area (BDA).

29 Maj 2012 15:51

Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet - Global Phase 3 program of SAR236553 / REGN727 to be initiated in June across multiple patient populations -

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 in patients with heterozygous familial hypercholesterolemia (heFH). SAR236553 / REGN727 is a subcutaneously administered, fully-human antibody targeting PCSK9 in clinical development.

21 Maj 2012 11:25

ASCO Abstracts Highlight Late-stage Sanofi Oncology Pipeline - Progress on Jevtana®, Zaltrap™ and JAK2 inhibitor featured

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today abstracts spanning the company’s innovative marketed and late-stage development compounds will be featured at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago, Ill., June 1-5. Sanofi products are noted in more than 170 abstracts to be presented at the meeting.

Visa mer Loading...